Last reviewed · How we verify
Xuesaitong soft capsule
At a glance
| Generic name | Xuesaitong soft capsule |
|---|---|
| Also known as | LixuwangⓇ |
| Sponsor | Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome (PHASE1, PHASE2)
- Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease (PHASE4)
- Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol (PHASE3)
- Efficacy and Safety of Xuesaitong Soft Capsule for Coronary Heart Disease Unstable Angina (PHASE2)
- The Study of MicroRNA Genomics of Blood Stasis Syndrome and of Coronary Heart Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: